Agenus Inc. - Common Stock (NQ:AGEN)

8.360 +0.030 (+0.36%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Agenus Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

Today 9:00 EDT

From Agenus Inc.

Via Business Wire

Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

September 10, 2026

From Agenus Inc.

Via Business Wire

Agenus to Participate in Upcoming September Investor Conferences

August 31, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

August 28, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer

August 26, 2026

From Agenus Inc.

Via Business Wire

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

August 06, 2026

From Agenus Inc.

Via Business Wire

Agenus to Provide Second Quarter 2026 Financial Report and Development Update

July 28, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026

July 17, 2026

From Agenus Inc.

Via Business Wire

Sphere 3D (NASDAQ: ANY) Engages Specialized Government Affairs Firms, Expands AI Infrastructure Strategy Across Tennessee Valley Authority Region

July 13, 2026

Via AB Newswire

Topics Artificial Intelligence

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer

July 13, 2026

From Agenus Inc.

Via Business Wire

Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026

July 06, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

June 25, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces Virtual 2026 Annual Shareholders Meeting

June 02, 2026

From Agenus Inc.

Via Business Wire

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

May 21, 2026

From Agenus Inc.

Via Business Wire

Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

May 21, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

May 15, 2026

From Agenus Inc.

Via Business Wire

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

May 11, 2026

From Agenus Inc.

Via Business Wire

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

May 04, 2026

From Agenus Bio

Via Business Wire

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

April 21, 2026

From Agenus Inc.

Via Business Wire

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

April 21, 2026

From Agenus Inc. & BAP Pharma

Via Business Wire

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

April 17, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

April 03, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

April 01, 2026

From Agenus Inc.

Via Business Wire

Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

March 26, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer

March 17, 2026

From Agenus Bio

Via Business Wire

Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

March 16, 2026

From Agenus Inc.

Via Business Wire

Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs

March 10, 2026

From Agenus Inc.

Via Business Wire

Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update

March 04, 2026

From Agenus Bio

Via Business Wire

Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL

February 19, 2026

From Agenus Bio

Via Business Wire

Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors

February 09, 2026

From Agenus Bio

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.